anti-BCMA bispecific T cell engager

An anti-BCMA bispecific T-cell engager (TCE) is a therapeutic bispecific antibody designed to treat multiple myeloma by recruiting and activating the patient's own T cells against malignant plasma cells. These molecules feature a dual-binding architecture: one domain targets the B-cell maturation antigen (BCMA), which is highly expressed on the surface of myeloma cells, while the other domain binds to the CD3 epsilon subunit of the T-cell receptor complex. By physically bridging the T cell and the tumor cell, the TCE induces the formation of an immunological synapse, triggering T-cell activation, the release of cytotoxic perforins and granzymes, and the subsequent lysis of the BCMA-positive tumor cell. This modality has shown significant efficacy in patients with relapsed or refractory multiple myeloma, with several agents such as teclistamab and elranatamab receiving regulatory approval.

Other names

anti-BCMA TCEBCMA-CD3 bispecific T-cell engagerBCMA-CD-3 bispecific T-cell engagerBCMA-CD 3 bispecific T-cell engagerBCMA-targeting bispecific antibodyBCMAxCD3 bispecific antibodyBCMAxCD-3 bispecific antibodyBCMAxCD 3 bispecific antibody